MONMOUTH JUNCTION, N.J.,
July 19, 2021 /PRNewswire/
-- CytoSorbents Corporation (NASDAQ: CTSO) a leader in the
treatment of life-threatening conditions in the intensive care unit
and cardiac surgery using blood purification via its proprietary
polymer adsorption technology, will report second quarter 2021
operating and financial results after the market close on
August 3, 2021.
CytoSorbents Corporation to Report Second Quarter 2021 Operating
and Financial Results on Tuesday, August 3,
2021
CytoSorbents' management will host a live conference call and
presentation webcast at 4:30 p.m.
Eastern the same day.
Conference call details:
Date: Tuesday, August 3, 2021
Time: 4:30 p.m. Eastern
Toll free: 1-877-451-6152
International: 1-201-389-0879
Conference ID: 13721110
Live presentation webcast:
http://public.viavid.com/index.php?id=145516
It is recommended that participants dial in approximately 10
minutes prior to the start of the call.
A simultaneous live webcast can be accessed via the following
audio feed: http://public.viavid.com/index.php?id=145516.
An archived recording of the conference call will be available
under the Investor Relations portion of the company's website at
https://cytosorbents.com/investor-relations/financial-results/
About CytoSorbents Corporation (NASDAQ: CTSO)
CytoSorbents Corporation is a leader in the treatment of
life-threatening conditions in the intensive care unit and cardiac
surgery using blood purification. Its flagship product,
CytoSorb® is approved in the European Union with distribution in 68
countries around the world, as an extracorporeal cytokine adsorber
designed to reduce the "cytokine storm" or "cytokine release
syndrome" seen in common critical illnesses that may result in
massive inflammation, organ failure and patient death. These are
conditions where the risk of death can be extremely high, yet few
to no effective treatments exist. CytoSorb is also being used
during and after cardiac surgery to remove inflammatory mediators
that can lead to post-operative complications, including multiple
organ failure. CytoSorb has been used in more than 131,000
human treatments to date. CytoSorb was originally introduced
into the European Union under CE-Mark as a first-in-kind cytokine
adsorber. Additional CE-Mark label expansions were received
for the removal of bilirubin and myoglobin in clinical conditions
such as liver disease and trauma, respectively, and both ticagrelor
and rivaroxaban during cardiothoracic surgery. CytoSorb has
also received FDA Emergency Use Authorization in the United States for use in critically ill
COVID-19 patients with imminent or confirmed respiratory
failure. CytoSorbents' technology has also been granted FDA
Breakthrough Designation for the removal of ticagrelor in a
cardiopulmonary bypass circuit during emergent and urgent
cardiothoracic surgery, and if FDA clearance is obtained, would be
marketed as DrugSorb-ATR™ in the United
States.
CytoSorbents' purification technologies are based on
biocompatible, highly porous polymer beads that can actively remove
toxic substances from blood and other bodily fluids by pore capture
and surface adsorption. Its technologies have received non-dilutive
grant, contract, and other funding of more than $39.5 million from DARPA, the U.S. Department of
Health and Human Services (HHS), the National Institutes of Health
(NIH), National Heart, Lung, and Blood Institute (NHLBI), the U.S.
Army, the U.S. Air Force, U.S. Special Operations Command (SOCOM),
Air Force Material Command (USAF/AFMC), and others. The Company has
numerous marketed products and products under development based
upon this unique blood purification technology protected by many
issued U.S. and international patents and registered trademarks,
and multiple patent applications pending, including ECOS-300CY®,
CytoSorb-XL™, HemoDefend-RBC™, HemoDefend-BGA™, VetResQ®,
K+ontrol™, DrugSorb™, DrugSorb-ATR™, ContrastSorb, and
others. For more information, please visit the
Company's websites at www.cytosorbents.com and www.cytosorb.com or
follow us on Facebook and Twitter.
Forward-Looking Statements
This press release includes forward-looking statements intended
to qualify for the safe harbor from liability established by the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, but are not limited to,
statements about our plans, objectives, representations and
contentions and are not historical facts and typically are
identified by use of terms such as "may," "should," "could,"
"expect," "plan," "anticipate," "believe," "estimate," "predict,"
"potential," "continue" and similar words, although some
forward-looking statements are expressed differently. You should be
aware that the forward-looking statements in this press release
represent management's current judgment and expectations, but our
actual results, events and performance could differ materially from
those in the forward-looking statements. Factors which could cause
or contribute to such differences include, but are not limited to,
the risks discussed in our Annual Report on Form 10-K, filed with
the SEC on March 9, 2021, as updated
by the risks reported in our Quarterly Reports on Form 10-Q, and in
the press releases and other communications to shareholders issued
by us from time to time which attempt to advise interested parties
of the risks and factors which may affect our business. We caution
you not to place undue reliance upon any such forward-looking
statements. We undertake no obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events, or otherwise, other than as required
under the Federal securities laws.
Please Click to Follow Us on Facebook and Twitter
CytoSorbents Investor Relations Contact:
Terri Anne Powers
Vice President of Investor Relations and Corporate
Communications
732-482-9984
tpowers@cytosorbents.com
Public Relations Contact:
Eric Kim
Rubenstein Public Relations
212-805-3052
ekim@rubensteinpr.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cytosorbents-to-report-second-quarter-2021-operating-and-financial-results-301336187.html
SOURCE CytoSorbents Corporation